Aurinia Pharmaceuticals
AUPH
64 hedge funds and large institutions have $145M invested in Aurinia Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 11 closing their positions.
35% more capital invested
Capital invested by funds: $107M → $145M (+$37.4M)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0.08% less ownership
Funds ownership: 25.28% → 25.2% (-0.08%)
4% less funds holding
Funds holding: 67 → 64 (-3)
21% less call options, than puts
Call options by funds: $2.41M | Put options by funds: $3.04M
27% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$1.19M |
| 2 |
D.E. Shaw & Co
New York
|
+$832K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$764K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$631K |
| 5 |
Franklin Resources
San Mateo,
California
|
+$591K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.06M |
| 2 |
O
OrbiMed
New York
|
-$943K |
| 3 |
Goldman Sachs
New York
|
-$510K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$453K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
-$312K |
AUPH Hedge Fund Activity: Q3 2018 in Review
64 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q3 2018, worth a combined $145M — up 35% from $107M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AUPH and 8 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 16 added.
The largest buyer was Polar Capital, adding an estimated $1.19M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.06M sold.
- 64 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q3 2018, down from 67 in Q2 2018.
- Funds reported $145M of Aurinia Pharmaceuticals stock for Q3 2018, up 35% quarter-over-quarter.
- 8 funds opened new Aurinia Pharmaceuticals positions in Q3 2018 and 11 closed out, a net change of -3 holders.
- The largest Aurinia Pharmaceuticals buyer in Q3 2018 was Polar Capital, an estimated $1.19M added.
- The largest Aurinia Pharmaceuticals seller in Q3 2018 was Alyeska Investment Group, an estimated $1.06M sold.
Based on aggregated 13F filings for Q3 2018.